Liminatus Pharma, Inc. Class A Common Stock (LIMN) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

Liminatus Pharma, Inc. Class A Common Stock (LIMN) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $4.8M, listed on NASDAQ, employing roughly 3 people, carrying a beta of 0.76 to the broader market. Liminatus Pharma, Inc. Led by Chris Kim, public since 2025-05-01.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for LIMN as of 2026-06-01; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →